Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Integragen stock

ALINT.PA
FR0010908723
A1J1JV

Price

0.74
Today +/-
+0.02
Today %
+2.06 %

Integragen stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Integragen stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Integragen stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Integragen stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Integragen's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Integragen Stock Price History

DateIntegragen Price
1/7/20250.74 undefined
1/6/20250.72 undefined
1/3/20250.65 undefined
1/2/20250.68 undefined
12/31/20240.57 undefined
12/30/20240.51 undefined
12/27/20240.53 undefined
12/24/20240.52 undefined
12/23/20240.53 undefined
12/20/20240.53 undefined
12/19/20240.53 undefined
12/18/20240.53 undefined
12/17/20240.53 undefined
12/16/20240.53 undefined
12/13/20240.54 undefined
12/12/20240.54 undefined
12/11/20240.53 undefined
12/10/20240.48 undefined
12/9/20240.49 undefined

Integragen Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Integragen, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Integragen from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Integragen’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Integragen. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Integragen’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Integragen’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Integragen’s growth potential.

Integragen Revenue, EBIT and net profit per share

DateIntegragen RevenueIntegragen EBITIntegragen Net Income
202213.21 M undefined-151,000 undefined-4,000 undefined
202111.32 M undefined-43,530 undefined15,410 undefined
20208.98 M undefined-254,140 undefined-375,020 undefined
20198.28 M undefined-363,070 undefined-284,840 undefined
20186.92 M undefined-1.18 M undefined-1.14 M undefined
20176.25 M undefined-1.93 M undefined-862,170 undefined
20166.02 M undefined-1.8 M undefined-1.65 M undefined
20155.58 M undefined-2.32 M undefined-1.53 M undefined
20146.04 M undefined-1.7 M undefined-1.04 M undefined
20135.41 M undefined-2.89 M undefined-2.55 M undefined
20124.74 M undefined-2.37 M undefined-1.73 M undefined
20114.65 M undefined-2.4 M undefined-2.04 M undefined
20103.21 M undefined-2.81 M undefined-2.9 M undefined
20092.81 M undefined-2.83 M undefined-2.73 M undefined
20082.26 M undefined-3.55 M undefined-3.66 M undefined
20072.36 M undefined-3.62 M undefined-3.35 M undefined

Integragen Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2007200820092010201120122013201420152016201720182019202020212022
222344565666881113
---50.0033.33-25.0020.00-16.6720.00--33.33-37.5018.18
250.00250.0050.0033.3350.0050.0040.0050.0060.0050.0050.0066.6762.5075.0063.6438.46
0011222333345675
-3-3-2-2-2-1-2-1-1-10-10000
---33.33---50.00100.00-50.00--------
0.622.652.973.773.774.314.174.975.035.025.016.466.486.636.636.63
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Integragen Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Integragen is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (k)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (k)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2007200820092010201120122013201420152016201720182019202020212022
                               
1.480.771.436.024.654.872.835.245.022.734.134.012.815.124.784.51
001.060.790.681.31.662.011.392.142.412.321.832.143.363.22
00790710560690450560540623.48846.42394.65528.85254.46309.06270
0037090180200230340270377.92360.06388.74289.75237.71341.55387
00450130140110120130130197.61158.33217.77237.75189.89183.39174
1.480.774.17.746.217.175.298.287.356.077.917.335.697.958.978.56
000.060.060.210.210.160.240.350.510.441.030.830.570.420.28
0050380540470310640730819.91145.24120.76155.87208.9748.41116
000000000000000267
00000010000.09000000
0000000000000000
000000010190192.46157.0396.5374.5792.95169.0176
000.110.440.750.680.480.891.271.520.741.251.060.870.630.74
1.480.774.218.186.967.855.779.178.627.598.658.586.758.829.69.3
                               
002.973.773.774.124.124.975.075.076.546.556.566.73.363.36
0024.8530.830.832.3332.3335.5936.1936.1838.2238.115.095.0800
00-26.54-29.44-31.48-33.21-35.75-36.79-38.33-39.97-40.83-41.87-9.14-9.62-1.18-1.18
0000000000000000
0000000000000000
001.285.133.093.240.73.772.931.283.932.792.512.172.192.18
000.640.360.641.171.391.21.21.651.131.550.70.91.771.61
000.660.740.991.131.061.611.852.041.321.961.722.532.211.61
001.141.190.70.960.990.931.041.091.721.631.391.151.481.93
1802409040000000000000
000000000000000548
0.180.242.532.332.333.263.443.744.094.784.175.143.814.585.465.7
000000000000.30.242.021.951.12
0000000000000000
000.380.721.551.361.661.671.61.530.550.350.190.050.010.02
000.380.721.551.361.661.671.61.530.550.650.432.071.961.14
0.180.242.913.053.884.625.15.415.696.314.725.794.246.657.426.84
0.180.244.198.186.977.865.89.188.627.598.658.586.758.829.69.02
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Integragen provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Integragen's financial health and stability.

Assets

Integragen's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Integragen must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Integragen after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Integragen's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2009
-2
0
0
0
0
0
0
-1
0
0
0
0
0
2
2
-
0
0
0
0

Integragen stock margins

The Integragen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Integragen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Integragen.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Integragen's sales revenue. A higher gross margin percentage indicates that the Integragen retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Integragen's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Integragen's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Integragen's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Integragen. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Integragen's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Integragen Margin History

Integragen Gross marginIntegragen Profit marginIntegragen EBIT marginIntegragen Profit margin
202240.73 %-1.14 %-0.03 %
202164.07 %-0.38 %0.14 %
202067.64 %-2.83 %-4.18 %
201969.02 %-4.38 %-3.44 %
201860.36 %-17.04 %-16.46 %
201753.45 %-30.89 %-13.8 %
201653.3 %-29.9 %-27.41 %
201554.66 %-41.58 %-27.42 %
201459.93 %-28.15 %-17.22 %
201353.23 %-53.42 %-47.13 %
201262.66 %-50 %-36.5 %
201152.9 %-51.61 %-43.87 %
201036.76 %-87.54 %-90.34 %
200940.21 %-100.71 %-97.15 %
200826.99 %-157.08 %-161.95 %
200741.1 %-153.39 %-141.95 %

Integragen Stock Sales Revenue, EBIT, Earnings per Share

The Integragen earnings per share therefore indicates how much revenue Integragen has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Integragen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Integragen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Integragen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Integragen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Integragen Revenue, EBIT and net profit per share

DateIntegragen Sales per ShareIntegragen EBIT per shareIntegragen Earnings per Share
20221.99 undefined-0.02 undefined-0 undefined
20211.71 undefined-0.01 undefined0 undefined
20201.35 undefined-0.04 undefined-0.06 undefined
20191.28 undefined-0.06 undefined-0.04 undefined
20181.07 undefined-0.18 undefined-0.18 undefined
20171.25 undefined-0.39 undefined-0.17 undefined
20161.2 undefined-0.36 undefined-0.33 undefined
20151.11 undefined-0.46 undefined-0.3 undefined
20141.22 undefined-0.34 undefined-0.21 undefined
20131.3 undefined-0.69 undefined-0.61 undefined
20121.1 undefined-0.55 undefined-0.4 undefined
20111.23 undefined-0.64 undefined-0.54 undefined
20100.85 undefined-0.75 undefined-0.77 undefined
20090.95 undefined-0.95 undefined-0.92 undefined
20080.85 undefined-1.34 undefined-1.38 undefined
20073.81 undefined-5.84 undefined-5.4 undefined

Integragen business model

IntegraGen SA is a French biotechnology company based in Evry. It was founded in 2000 and is one of the leading companies in developing commercial applications in genomics and biology. The business model of IntegraGen SA consists of providing solutions and services for the diagnosis and treatment of various diseases, such as cancer, neurodegenerative diseases, and other genetically related diseases. The company is divided into two main areas: Diagnostics and Genomics. The Diagnostics area offers a wide range of services to its customers, including an oncology platform for the diagnosis and prediction of cancer using exclusive biomarker sets. Other diagnostic tests are used for the identification of microorganisms in clinical samples and the detection of autoimmune diseases. In the Genomics area, the focus is on the development and sale of PCR kits for genotyping single nucleotide polymorphisms (SNPs) and analysis kits for RNA expression. These solutions allow for the identification and validation of genes in specific biological samples in a way that improves customers' understanding and enables accurate findings. IntegraGen SA is committed to continuously developing new tests and platforms to help its customers achieve more precise diagnoses and better therapies. One notable development of the company is the screening kit "Arisk," which is specifically designed for identifying genotypes that have an increased risk of colorectal cancer. The screening kit uses specific SNPs to ensure that doctors can identify patients who require increased monitoring or even prophylactic surgery. The use of genomics technology and biomarker-based diagnostics is a growing trend in medicine. IntegraGen SA plays a significant role in enabling the integration of genomics into clinical practice, ensuring the best possible diagnosis and treatment for patients. In summary, IntegraGen SA is an innovative biotechnology company dedicated to providing solutions for the diagnosis and prevention of diseases using various technologies. The company is constantly striving to develop new products and services to provide customers and partners with the best possible diagnostic and therapeutic support. Integragen is one of the most popular companies on Eulerpool.com.

Integragen SWOT Analysis

Strengths

Integragen SA possesses several strengths that contribute to its competitive advantage:

  • Strong Research and Development (R&D) capabilities
  • Advanced and innovative technology
  • Skilled and experienced workforce

Weaknesses

Despite its strengths, Integragen SA also faces certain weaknesses:

  • Dependence on a limited number of key clients
  • Relatively small market share
  • Financial dependency on external funding

Opportunities

Integragen SA can leverage the following opportunities to drive growth:

  • Expanding into new geographic markets
  • Contacting strategic partnerships and collaborations
  • Increasing demand for personalized medicine

Threats

Integragen SA must be aware of the following threats that could impact its business:

  • Intense competition in the genomics industry
  • Regulatory hurdles and compliance requirements
  • Economic downturns and market volatility
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Integragen Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Integragen historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Integragen shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Integragen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Integragen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Integragen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Integragen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Integragen.

Integragen shareholders

%
Name
Stocks
Change
Date
65.86881 % Oncodna SA4,432,971012/31/2023
0 % Trusteam Finance0-117,1172/29/2024
1

Most common questions regarding Integragen

What values and corporate philosophy does Integragen represent?

Integragen SA represents strong values and a unique corporate philosophy. With a focus on innovation and scientific excellence, Integragen SA constantly strives to provide cutting-edge genetic solutions to its clients. The company's commitment to quality and precision enables them to offer personalized healthcare and diagnostic services, catering to the individual needs of each patient. Integragen SA prioritizes ethical practices and values collaboration, fostering partnerships with leading research institutions and healthcare providers. By harnessing the power of genomics, Integragen SA aims to improve patient outcomes and contribute to the advancement of precision medicine.

In which countries and regions is Integragen primarily present?

Integragen SA is primarily present in France, the United States, and Belgium.

What significant milestones has the company Integragen achieved?

Integragen SA, a leading company in the field of genomics, has achieved numerous significant milestones. One notable achievement is their development of innovative genomic solutions, catering to the needs of both academic researchers and healthcare professionals. By leveraging their advanced technology and expertise, Integragen SA has successfully provided high-quality genomic sequencing and analysis services to various institutions and organizations. Additionally, the company has made significant contributions to the development of personalized medicine, allowing for better understanding and treatment of complex diseases. Integragen SA's commitment to excellence and continual innovation has positioned them as a prominent player in the genomics industry, driving advancements in healthcare and research.

What is the history and background of the company Integragen?

Integragen SA, founded in 2000, is a leading biotechnology company specializing in genomic solutions for personalized medicine. Headquartered in France, the company focuses on the development and implementation of advanced genomic testing methods. With a strong background in genetic research, Integragen SA offers comprehensive molecular diagnostics and innovative solutions for disease management. Its expertise lies in genetic sequencing, bioinformatics, and data analysis, enabling it to provide personalized insights into various medical conditions. Integragen SA's commitment to revolutionizing healthcare through genomics has established it as a trusted partner in the advancement of personalized medicine.

Who are the main competitors of Integragen in the market?

The main competitors of Integragen SA in the market include Genomic Health Inc., Foundation Medicine Inc., and Veracyte Inc.

In which industries is Integragen primarily active?

Integragen SA is primarily active in the field of genetic sequencing and molecular diagnostics for cancer and autism. This French biotechnology company specializes in providing innovative solutions and services to healthcare professionals and researchers. With its cutting-edge technology and expertise in genomics, Integragen SA aims to improve patient care and advance scientific discoveries in these critical areas.

What is the business model of Integragen?

Integragen SA is a leading company specializing in innovative genomic services and molecular diagnostics. Their business model revolves around providing personalized healthcare solutions through cutting-edge genetic analysis and bioinformatics. By leveraging their expertise in advanced sequencing technologies, Integragen offers accurate and reliable genetic testing services to improve patient care. They prioritize collaboration with healthcare professionals and researchers to deliver customized genomic insights for a range of applications, including cancer diagnostics, rare diseases, and pharmacogenomics. Integragen SA's commitment to leveraging genomics for better health outcomes makes them an esteemed player in the field of precision medicine.

What is the P/E ratio of Integragen 2025?

The P/E ratio cannot be calculated for Integragen at the moment.

What is the P/S ratio of Integragen 2025?

The P/S cannot be calculated for Integragen currently.

What is the Quality Investing of Integragen?

The Quality Investing for Integragen is 2/10.

What is the revenue of Integragen 2025?

The revenue cannot currently be calculated for Integragen.

How high is the profit of Integragen 2025?

The profit cannot currently be calculated for Integragen.

What is the business model of Integragen

Integragen SA is a company specialized in the development and sale of genetic tests and data analysis. The company was founded in 2000 and is headquartered in Evry, France. Its core business is DNA sequencing and analysis, conducting genome studies, pharmacogenomics, biomarker development, precise diagnostics, and personalized medicine. Integragen has three core divisions: Biopharmaceuticals, Medical Genomics, and Research Support. It offers services to support biotech and pharmaceutical companies in developing personalized medicines, assists healthcare professionals in identifying genetic changes in patients, and provides comprehensive genomics services for genetic research. The company also offers various genetic tests for cancer prevention and diagnosis, assessing the risk of cardiovascular diseases, and grouping metabolism processes. Integragen has a wide network of partners in the biotech and pharmaceutical industry, as well as academia, and aims to expand its business through strategic partnerships and acquisitions. In summary, Integragen is a leading company in the genomics industry with a wide range of services and products, focusing on personalized medicine and genetic research to drive growth in the coming years.

What is the Integragen dividend?

Integragen pays a dividend of 0 EUR distributed over payouts per year.

How often does Integragen pay dividends?

The dividend cannot currently be calculated for Integragen or the company does not pay out a dividend.

What is the Integragen ISIN?

The ISIN of Integragen is FR0010908723.

What is the Integragen WKN?

The WKN of Integragen is A1J1JV.

What is the Integragen ticker?

The ticker of Integragen is ALINT.PA.

How much dividend does Integragen pay?

Over the past 12 months, Integragen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Integragen is expected to pay a dividend of 0 EUR.

What is the dividend yield of Integragen?

The current dividend yield of Integragen is .

When does Integragen pay dividends?

Integragen pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Integragen?

Integragen paid dividends every year for the past 0 years.

What is the dividend of Integragen?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Integragen located?

Integragen is assigned to the 'Health' sector.

Wann musste ich die Aktien von Integragen kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Integragen from 1/7/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 1/7/2025.

When did Integragen pay the last dividend?

The last dividend was paid out on 1/7/2025.

What was the dividend of Integragen in the year 2024?

In the year 2024, Integragen distributed 0 EUR as dividends.

In which currency does Integragen pay out the dividend?

The dividends of Integragen are distributed in EUR.

All fundamentals about Integragen

Our stock analysis for Integragen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Integragen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.